Related references
Note: Only part of the references are listed.mTORC1 and mTORC2 in cancer and the tumor microenvironment
L. C. Kim et al.
ONCOGENE (2017)
Heterogeneous nuclear ribonucleoprotein M associates with mTORC2 and regulates muscle differentiation
Wei-Yen Chen et al.
SCIENTIFIC REPORTS (2017)
Robust stratification of breast cancer subtypes using differential patterns of transcript isoform expression
Thomas P. Stricker et al.
PLOS GENETICS (2017)
mTOR Signaling in Growth, Metabolism, and Disease
Robert A. Saxton et al.
CELL (2017)
The PI3K/AKT Pathway as a Target for Cancer Treatment
Ingrid A. Mayer et al.
ANNUAL REVIEW OF MEDICINE, VOL 67 (2016)
Rbfox Proteins Regulate Splicing as Part of a Large Multiprotein Complex LASR
Andrey Damianov et al.
CELL (2016)
Alternative splicing and cell survival: from tissue homeostasis to disease
Maria Paola Paronetto et al.
CELL DEATH AND DIFFERENTIATION (2016)
Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases
Jing Ni et al.
NATURE MEDICINE (2016)
Therapeutic targeting of splicing in cancer
Stanley Chun-Wei Lee et al.
NATURE MEDICINE (2016)
Mammalian Target of Rapamycin: Its Role in Early Neural Development and in Adult and Aged Brain Function
Carla Garza-Lombo et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2016)
Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review
Zebo Huang et al.
FUTURE ONCOLOGY (2015)
Genotoxic stress inhibits ewing sarcoma cell growth by modulating alternative pre-mRNA processing of the RNA helicase DHX9
Marco Fidaleo et al.
ONCOTARGET (2015)
MLN0128, an ATP-Competitive mTOR Kinase Inhibitor with Potent In Vitro and In Vivo Antitumor Activity, as Potential Therapy for Bone and Soft-Tissue Sarcoma
Emily K. Slotkin et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia
N. Sandhoefer et al.
LEUKEMIA (2015)
The ets transcription factor Fli-1 in development, cancer and disease
Y. Li et al.
ONCOGENE (2015)
NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate
Berengere Gobin et al.
CANCER LETTERS (2014)
Cell type-restricted activity of hnRNPM promotes breast cancer metastasis via regulating alternative splicing
Yilin Xu et al.
GENES & DEVELOPMENT (2014)
Both Decreased and Increased SRPK1 Levels Promote Cancer by Interfering with PHLPP- Mediated Dephosphorylation of Akt
Pingping Wang et al.
MOLECULAR CELL (2014)
PI3K and cancer: lessons, challenges and opportunities
David A. Fruman et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Context-dependent control of alternative splicing by RNA-binding proteins
Xiang-Dong Fu et al.
NATURE REVIEWS GENETICS (2014)
A day in the life of the spliceosome
A. Gregory Matera et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition
Ilaria Passacantilli et al.
ONCOTARGET (2014)
Regulation of FAS Exon Definition and Apoptosis by the Ewing Sarcoma Protein
Maria Paola Paronetto et al.
CELL REPORTS (2014)
mTOR in aging, metabolism, and cancer
Marion Cornu et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2013)
The Akt-SRPK-SR Axis Constitutes a Major Pathway in Transducing EGF Signaling to Regulate Alternative Splicing in the Nucleus
Zhihong Zhou et al.
MOLECULAR CELL (2012)
The spliceosome as a target of novel antitumour drugs
Sophie Bonnal et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Integrative Genome-wide Analysis Reveals Cooperative Regulation of Alternative Splicing by hnRNP Proteins
Stephanie C. Huelga et al.
CELL REPORTS (2012)
The Ewing Sarcoma Protein Regulates DNA Damage-Induced Alternative Splicing
Maria Paola Paronetto et al.
MOLECULAR CELL (2011)
Understanding splicing regulation through RNA splicing maps
Joshua T. Witten et al.
TRENDS IN GENETICS (2011)
NVP-BEZ235 as a New Therapeutic Option for Sarcomas
Maria C. Manara et al.
CLINICAL CANCER RESEARCH (2010)
Cotranscriptional exon skipping in the genotoxic stress response
Martin Dutertre et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2010)
Global regulation of alternative splicing during myogenic differentiation
Christopher S. Bland et al.
NUCLEIC ACIDS RESEARCH (2010)
Recent advances in the molecular pathogenesis of Ewing's sarcoma
E. C. Toomey et al.
ONCOGENE (2010)
The Spliceosome: Design Principles of a Dynamic RNP Machine
Markus C. Wahl et al.
CELL (2009)
Co-transcriptional splicing of constitutive and alternative exons
Amy Pandya-Jones et al.
RNA (2009)
Childhood and Adolescent Cancer Survival in the US by Race and Ethnicity for the Diagnostic Period 1975-1999
Amy M. Linabery et al.
CANCER (2008)
Multiple alternative splicing markers for ovarian cancer
Roscoe Klinck et al.
CANCER RESEARCH (2008)
Identification of Alternative Splicing Markers for Breast Cancer
Julian P. Venables et al.
CANCER RESEARCH (2008)
Targeting insulin-like growth factor 1 receptor in sarcomas
Katia Scotlandi et al.
CURRENT OPINION IN ONCOLOGY (2008)
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies
Monica M. Mita et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Heterogeneous ribonucleoprotein M is a splicing regulatory protein that can enhance or silence splicing of alternatively spliced Exons
Ruben H. Hovhannisyan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Rapamycin: Something old, something new, sometimes borrowed and now renewed
C. M. Hartford et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival
Emanuel F. Petricoin et al.
CANCER RESEARCH (2007)
MTOR, translation initiation and cancer
Y. Mamane et al.
ONCOGENE (2006)
Profiling alternatively spliced mRNA isoforms for prostate cancer classification
CL Zhang et al.
BMC BIOINFORMATICS (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Quantitative microarray profiling provides evidence against widespread coupling of alternative splicing with nonsense-mediated mRNA decay to control gene expression
Q Pan et al.
GENES & DEVELOPMENT (2006)
Concerted regulation of nuclear and cytoplasmic activities of SR proteins by AKT
M Blaustein et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2005)
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition
SY Sun et al.
CANCER RESEARCH (2005)
Understanding alternative splicing: Towards a cellular code
AJ Matlin et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2005)
Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation
S Mateo-Lozano et al.
ONCOGENE (2003)
Neoadjuvant chemotherapy for Ewing's tumour of bone: recent experience at the Rizzoli Orthopaedic Institute
G Bacci et al.
EUROPEAN JOURNAL OF CANCER (2002)
Large-scale proteomic analysis of the human splicesome
J Rappsilber et al.
GENOME RESEARCH (2002)
Alternative pre-mRNA splicing:: the logic of combinatorial control
CWJ Smith et al.
TRENDS IN BIOCHEMICAL SCIENCES (2000)
Share Paper
